Repositioning Candidate Details
| Candidate ID: | R1236 |
| Source ID: | DB09165 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Technetium Tc-99m pyrophosphate |
| Synonyms: | Technetium (99mTc) pyrophosphate; Technetium TC 99M Pyrophosphate |
| Molecular Formula: | O7P2Tc |
| SMILES: | [99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O |
| Structure: |
|
| DrugBank Description: | A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. |
| CAS Number: | 52997-54-3 |
| Molecular Weight: | 272.847 |
| DrugBank Indication: | For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction . May also be used to image gated blood pools and detect gastrointetinal bleeding. |
| DrugBank Pharmacology: | Technetium Tc-99m pyrophosphate collects in areas of altered osteogenesis and injured myocardium. It also has an affinity for red blood cells, enabling imaging of blood pools. |
| DrugBank MoA: | It is thought that technetium Tc-99m pyrophosphate is adsorbed onto the surface of amorphous calcium phosphate deposits , insoluble hydroxyapatite crystals, and possibly other organic macromolecules. This would result in selective localization to necrotic muscle tissue such as that of a myocardial infarction where calcium deposition has begun as a result of cell damage. In areas of altered osteogenesis where hydroxyapatite formation is actively occuring, the surface area to volume ratio is high and favors a greater amount of technetium Tc-99m pyrophosphate to the surface of the crystals than in other areas of bone where crystal formation is less active. The localization of technetium Tc-99m pyrophosphate to these areas allows for their specific radioimaging. |
| Targets: | Hydroxyapatite ligand; Amorphous calcium phosphate ligand |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |